Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Julia Glade Bender et al.|The Lancet Oncology|2019Cited by 341
Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout diseaseKiersten Ricci, Denise M. Adams, Adrienne M. Hammill et al.|Pediatric Blood & Cancer|2019Cited by 126
Opportunities and Challenges in Drug Development for Pediatric CancersTheodore W. Laetsch, Lucas Moreno, Steven G. DuBois et al.|Cancer Discovery|2020Cited by 70
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Julie R. Park, Steven G. DuBois et al.|Pediatric Blood & Cancer|2018Cited by 39